Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
MRNA.US
id: 1303

Moderna (MRNA) Vaccine Effectiveness Case

The defendant has requested the court to dismiss the case.
D. Massachusetts
Court
1:24-cv-12058
Case number
01/18/2023
Class period Start
06/25/2024
Class period End
10/08/2024
Lead Plaintiff motion deadline

  • $MRNA stockholders filed a claim against Moderna for misleading them about the effectiveness of its vaccine, overstating its potential.

  • After the news about the vaccine on June 26, 2024, $MRNA fell by 11%.

  • Moderna investors can join this case to be notified about potential recovery.

Case Details:

On May 31, 2024, Moderna's FDA-approved RSV vaccine showed a 78.7% efficacy, lower than the expected 83.7%.

On this news, $MRNA fell 5.9% on May 31, 2024.

Then, on June 26, 2024, Moderna revealed that its RSV vaccine’s effectiveness dropped to around 50% after 18 months, lower than competitors' vaccines.

After that, $MRNA fell 11% on the same day.

Based on these events, a $MRNA stockholder filed a claim against Moderna and its leaders, accusing them of the following:

  • Moderna's mRNA-1345 vaccine was less effective than claimed.

  • As a result, its clinical and commercial potential was overstated.

Considering all the representations, investors suspect Moderna misled them about the effectiveness of its vaccine, overstating its potential.

Case Type
US Securities Class Action
Case Status
Motion to dismiss
Alleged Offence
Mismanagement, 
Misleading Statements, 
Omissions
Suspected Party
Directors, 
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
05/02/2024
Filing date
08/09/2024
Lead Plaintiff Deadline
10/08/2024